Cationic Nanohydrogel Particles for Therapeutic Oligonucleotide Delivery

Area of Science:

• Biotechnology
• Materials Science
• Pharmacology

Background:

• Short pharmaceutical active oligonucleotides, including small interfering RNA (siRNA) and cytidine-phosphate-guanosine (CpG), show therapeutic potential for challenging diseases like liver fibrosis and cancer.
• However, their clinical application is hindered by poor pharmacokinetic properties, limiting their effective delivery and therapeutic translation.
• Nanosized carriers present a viable strategy to enhance oligonucleotide delivery and target specific sites of action.

Purpose of the Study:

• To explore cationic nanohydrogel particles as a universal delivery system for anionic oligonucleotides (siRNA and CpG).
• To highlight the potential of these nanocarriers for in vitro and in vivo oligonucleotide delivery, particularly in liver fibrosis therapies and immune system modulation.

Main Methods:

• Development of well-defined cationic nanohydrogel particles derived from preaggregated precursor block copolymers.
• Cross-linking of precursor polymers to form nanoparticles with tunable sizes and degradable cationic cores.
• Focus on covalent stabilization of carrier systems for advanced oligonucleotide therapeutics.

Main Results:

• Cationic nanohydrogels demonstrate potential as effective carriers for small anionic molecules like siRNA and CpG.
• The tunable nature of these nanoparticles allows for optimized delivery and targeting.
• The study highlights opportunities for oligonucleotide delivery in liver fibrosis and immune modulation.

Conclusions:

• Cationic nanohydrogel particles represent a versatile and effective platform for delivering therapeutic oligonucleotides.
• This approach offers a pathway to overcome pharmacokinetic limitations and advance oligonucleotide-based therapies.
• The covalent stabilization of these carrier systems holds promise for future drug development in treating complex diseases.